Axsome Therapeutics announced preliminary fourth quarter and full year 2025 net product revenues for AUVELITY, SUNOSI, and SYMBRAVO.
Total preliminary 4Q 2025 net product revenue: $196.0 million, representing 65% annual growth.
Total full year 2025 net product revenue: $638.5 million, representing 66% annual growth.
Axsome's strong financial performance in 2025 showcases its commitment to advancing treatment for central nervous system (CNS) disorders through AUVELITY, SUNOSI, and SYMBRAVO.
AUVELITY Sales
Preliminary 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively, indicate robust demand for the treatment of CNS disorders.
SUNOSI Revenue
Preliminary 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively, demonstrate significant market acceptance and growth potential.
SYMBRAVO Sales
Preliminary 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively, highlight the successful commercial launch of a new treatment option in 2025.
- Axsome's impressive 65% annual growth in net product revenues for Q4 2025 compared to 2024 indicates strong market traction and revenue expansion strategies.
- The positive sales results of AUVELITY, SUNOSI, and SYMBRAVO reflect Axsome's strategic focus on developing innovative treatments for CNS disorders, driving both revenue growth and patient outcomes.
- The commercial launch of SYMBRAVO in June 2025 significantly contributed to Axsome's overall net product sales for the full year, demonstrating successful expansion into new therapeutic areas and market segments.
Axsome Therapeutics' strong financial results for the fourth quarter and full year 2025 underscore its commitment to disrupting the CNS treatment market with innovative therapies, driving substantial revenue growth and positioning the company as a key player in the biopharmaceutical industry.